AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
kundkonton
FxPro har tillhandahållit online-handelstjänster till klienter sedan 1999 och de betjänar för närvarande 173 länder världen över.
Utmärkelser
FxPro har fått konstant erkännande i branschen och vunnit över 145 internationella utmärkelser hittills för kvaliteten på deras tjänster.
kundservice
Vårt dedikerade, flerspråkiga kundservice-team arbetar 24/5 för att ge dig en exceptionell nivå av support.
branschregler
FxPro verkar under strikt tillsyn i flera jurisdiktioner, inklusive auktorisation av FCA i Storbritannien — en av de mest betrodda finansiella tillsynsmyndigheterna i världen.
